ENB Therapeutics completes Phase 1 trial enrollment for ENB-003
ENB Therapeutics, a biotechnology firm working on therapeutics targeting the endothelin B receptor (ETBR), announced the completion of its international Phase 1 ENBOLDEN-101 trial enrollment. The trial aims to investigate the safety and efficacy of ENB-003, the company’s lead product, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab). This Phase 1/2a study is an open-label, […]